To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
74856665AML1001A Phase 1, First in Human (FIH), Dose Escalation Study of JNJ-74856665 (dihydroorotate dehydrogenase [DHODH] Inhibitor) in Participants with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | |
---|---|
Local Project Reference: | 135994 |
Principal Investigator: | Dr. Jenny O'Nions |
Drug Class/ Treatrment: | Dihydroorotate Dehydrogenase (DHODH) Inhibitor: JNJ-74856665 Arm A: Monotherapy Arm B: Combination with Azacitidine (AZA) |
Patient Population: | Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CCS1477-02An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with advanced haematological malignancies | |
---|---|
Local Project Reference: | 121140 |
Principal Investigator: | Dr. Jenny O'Nions |
Drug Class/ Treatrment: | P300/CBP Inhibitor: CCS1477 Monotherapy |
Patient Population: | Advanced Haematological Malignancies |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
EP0042-101A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate theSafety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies. | |
---|---|
Local Project Reference: | 134892 |
Principal Investigator: | Dr. Jenny O'Nions |
Drug Class/ Treatrment: | FLT3 inhibitor & Aurora Kinase Inhibitor: EP0042 Oral administration |
Patient Population: | Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndromes (MDS) |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CL1-65487-003Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multicentre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl2 inhibitor combined with azacitidine in adult patients with previously untreated acute myeloid leukemia not eligible for intensive treatment | |
---|---|
Local Project Reference: | 136715 |
Principal Investigator: | Dr. Jenny O'Nions |
Drug Class/ Treatrment: | BCL2 Inhibitor: S65487 Combination S65487 and Azacitidine. Receiving 7 days Azacitidne and weekly S65487 infusions through the vein every 28 days. |
Patient Population: | Acute Myeloid Leukaemia |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
PROMISEInvestigation into the combination of PLX2853 with Ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone. | |
---|---|
Local Project Reference: | 136172 |
Principal Investigator: | Dr. Jenny O'Nion |
Drug Class/ Treatrment: | PLX2853 (BET Inhibitor) + Ruxolitinib (JAK Inhibitor) |
Patient Population: | Intermediate or High-Risk Myelofibrosis |
Trial Hosted By - NIHR UCLH Clinical Research Facility (CRF) |
CPI-0610 / MANIFESTCPI-0610 With or Without Ruxolitinib - A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) | |
---|---|
Local Project Reference: | 18/0336 |
Principal Investigator: | Dr. Mallika Sekhar |
Drug Class/ Treatrment: | CPI-0610 - BET Inhibitor Monotherapy or with Ruxolitinib - JAK1 and JAK2 Inhibitor |
Patient Population: | Phase 2 - Myelofibrosis |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
SeluDexSeluDex: International phase I/II expansion trial of the MEK inhibitor selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult Acute Lymphoblastic Leukaemia | |
---|---|
Local Project Reference: | 18/0068 |
Principal Investigator: | Prof. Adele Fielding |
Drug Class/ Treatrment: | Selumetinib (MEK Inhibitor) + Dexamethasone |
Patient Population: | Relapsed/Refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
AUTO-1AUTO1 in relapsed or refractory B-ALL : AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA | |
---|---|
Local Project Reference: | 127550 |
Principal Investigator: | Dr. Claire Roddie |
Drug Class/ Treatrment: | AUTO1 (CAR T-Cell Therapy Targeting CD19) |
Patient Population: | RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
FEDORAFEDORA : A phase II study to evaluate the tolerability, safety and activity of fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis | |
---|---|
Local Project Reference: | 146196 |
Principal Investigator: | Dr. Donal McLornan |
Drug Class/ Treatrment: | Fedratanib (JAK2 Inhibitor) + Ropeginterferon Alfa-2b (Pegylated Interferon) |
Patient Population: | Myelofibrosis |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
ELECTRAA Phase 1b, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ELA026 in Adults and Adolescents with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) | |
---|---|
Local Project Reference: | 145018 |
Principal Investigator: | Dr. Satyen Gohil |
Drug Class/ Treatrment: | ELA026 (IgG1 SIRP-Directed Monoclonal Antibody) |
Patient Population: | Secondary Hemophagocytic Lymphohistiocytosis (sHLH) Adults and Adolescents (≥12 years at the time of HLH diagnosis) |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |